治験レーダーAI | ||
|---|---|---|
治験 NCT04589845（対象：固形腫瘍）は募集中です。詳細は治験レーダーのタイル表示と AI 発見ツールで確認するか、ここで質問してください。 | ||
フィルター基準に一致する試験が1件見つかりました
タイル表示
検索に戻る
ロシュTumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You（TAPISTRY）プラットフォーム試験 第II相・フェーズ2 920 免疫療法 非盲検
治験（臨床試験）の詳細は主に英語で提供されていますが、治験レーダーAIがサポートします！「治験解説」をクリックして、選択した言語で試験情報を表示し、議論してください。
治験番号 NCT04589845 は 固形腫瘍 に関する 治療 の研究で、第II相・フェーズ2 介入研究 臨床試験 です。現在は 募集中 で、2021年1月18日 から開始しています。920 名の参加者 の募集が計画されています。この試験は ロシュ によって主導され、2032年9月25日 に完了予定です。ClinicalTrials.gov からの最新更新日は 2026年3月6日 です。
概要
TAPISTRY is a Phase II, global, multicenter, open-label, multi-cohort study designed to evaluate the safety and efficacy of targeted therapies or immunotherapy as single agents or in rational, specified combinations in participants with unresectable, locally advanced or metastatic solid tumors determined to harbor specific oncogenic genomic alterations or who are tumor mutational burden (TMB)-high as identified by a ...もっと見る
公式タイトル
Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Phase II Platform Trial
疾患名
固形腫瘍刊行物
この臨床試験について発表された科学記事と研究論文：その他の研究識別子
- BO41932
- 2020-001847-16 (EudraCT番号)
- 2023-507418-28-00 (EU試験（CTIS）番号)
主目的
治療
割付方法
非無作為化
介入モデル
並行割当
盲検化
なし（非盲検）
群（アーム）／介入
| 参加グループ/群 | 介入/治療法 |
|---|---|
実験的Cohort A: ROS Proto-oncogene 1 (ROS1) Fusion-positive Tumors (Excluding NSCLC) Participants with metastatic or advanced solid tumors, with the exception of non-small cell lung cancer (NSCLC), will receive entrectinib once daily (QD) in repeated 28-day cycles at a dose of 600 milligram per day (mg/day) for adults and pediatric participants with a body surface area (BSA) ≥ 1.51 square meter (m\^2). The total dose of daily entrectinib administration for pediatric participants with BSA \< 1.51 m\^2...もっと見る | Entrectinib Adults and pediatric participants with a BSA ≥1.51 m\^2: entrectinib will be self-administered by participants orally at home at a dose of 600 mg/day (three 200-mg capsules per day). Pediatric participants with a BSA \< 1.51 m\^2: entrectinib will be administered orally at home in mini-tablet formulation at a dose of 400 mg/day (BSA=1.11-1.50 m\^2) or 300 mg/day (BSA=0.81-1.10 m\^2) or 200 mg/day (BSA=0.51-0.80 m\^2)...もっと見る |
実験的Cohort B: Neurotrophic Tyrosine Receptor Kinase (NTRK) 1/2/3 Fusion-positive Tumors Participants with metastatic or advanced solid tumors will receive entrectinib, QD in repeated 28-day cycles at a dose of 600 mg/day for adults and pediatric participants with a BSA ≥ 1.51 m\^2. The total dose of daily entrectinib administration for pediatric participants with BSA \< 1.51 m\^2 will be lower. | Entrectinib Adults and pediatric participants with a BSA ≥ 1.51 m\^2: entrectinib will be self-administered by participants orally at home at a dose of 600 mg/day (three 200-mg capsules per day). Pediatric participants with a BSA \< 1.51 m\^2: entrectinib will be administered orally at home in mini-tablet formulation at a dose of 400 mg/day (BSA=1.11-1.50 m\^2) or 300 mg/day (BSA=0.81-1.10 m\^2) or 200 mg/day (BSA=0.51-0.80 m\^2...もっと見る |
実験的Cohort C: Anaplastic Lymphoma Kinase (ALK) Fusion-positive Tumors (Excluding NSCLC) Participants with metastatic or advanced solid tumors, with the exception of NSCLC, will receive alectinib at a dosage of 600 mg, orally, twice a day (BID), taken with food, in repeated 28-day cycles. | Alectinib Alectinib will be administered orally BID with food at a dosage of 600 mg (four 150-mg capsules). |
実験的Cohort D: TMB-high Tumors Participants with metastatic or advanced solid tumors will receive atezolizumab intravenously (IV) at a fixed dose for participants aged ≥ 18 years, and 15 milligrams per kilogram (mg/kg) (maximum 1200 mg) for participants aged \< 18 years on Day 1 of each 21-day cycle. Note: Cohort D has been closed for enrollment. | Atezolizumab Atezolizumab will be administered by IV infusion at a fixed dose of 1200 mg for participants aged ≥18 years, and 15 mg/kg (maximum 1200 mg) for participants aged \<18 years on Day 1 of each 21-day cycle. |
実験的Cohort E: Protein Kinase B (AKT) 1/2/3 Mutant-positive Tumors Participants with metastatic or advanced solid tumors will receive ipatasertib orally, QD at the starting dose of 400 mg in repeated 28-day cycles until the participant experiences disease progression, intolerable toxicity, or withdraws consent. For participants 12-17 years of age, ipatasertib will be administered at the starting dose of 200 mg for participants \< 35 kilograms (kg), 300 mg for participants ≥ 35 and \...もっと見る | Ipatasertib For participants 12-17 years of age, ipatasertib will be administered at the starting dose of 200 mg for participants \< 35 kg, 300 mg for participants ≥35 and \< 45 kg, 400 mg for those ≥ 45 kg orally QD, beginning of Cycle 1, on Days 1-21 of each 28-day cycle until the participant experiences disease progression, intolerable toxicity, or withdraws consent. |
実験的Cohort F: Human Epidermal Growth Factor Receptor 2 (HER2) Mutant-positive Tumors Participants with metastatic or advanced solid tumors will receive trastuzumab emtansine IV at a dose of 3.6 mg/kg every 21 days.
Note: Cohort F has been closed as of protocol version 7 because enrollment and participant follow-up have been completed. | Trastuzumab emtansine Trastuzumab emtansine will be administered at 3.6 mg/kg by IV infusion every 21 days until disease progression or unacceptable toxicity. The dosage and administration method also applies for pediatric participants 12-17 years of age. |
実験的Cohort H: PIK3CA Multiple Mutant-positive Tumors Participants with phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA) multiple mutant-positive tumors will receive inavolisib (GDC-0077) QD at a starting dose of 9 mg by mouth (PO) in repeated 28-day cycles. Note: Cohort H has been closed for enrollment. | Inavolisib GDC-077 will be administered QD at a starting dose of 9 mg PO in repeated 28-day cycles. The dosage and administration method also applies for pediatric participants 12-17 years of age. |
実験的Cohort I: BRAF Class II Mutant or Fusion-positive Tumors Participants with proto-oncogene B-Raf (BRAF) class II mutant/fusion-positive tumors (adults and adolescents ≥ 40 kg) will receive 400 mg belvarafenib, PO, BID with adequate water (more than 200 milliliters \[mL\]). One cycle consists of 28 days. Administration of belvarafenib should occur BID on every day of each 28-day cycle. Note: Cohort I has been closed for enrollment. | Belvarafenib Belvarafenib will be administered at a dose 400 mg, PO, BID with adequate water (more than 200 mL). One cycle consists of 28 days. Administration of belvarafenib should occur BID on every day of each 28-day cycle. |
実験的Cohort J: BRAF Class III Mutant-positive Tumors Participants with BRAF class III mutant-positive tumors (adults and adolescents ≥ 40 kg) will receive 400 mg belvarafenib PO BID with adequate water (more than 200 mL). One cycle consists of 28 days. Administration of belvarafenib should occur BID on every day of each 28-day cycle. Note: Cohort J has been closed for enrollment. | Belvarafenib Belvarafenib will be administered at a dose 400 mg, PO, BID with adequate water (more than 200 mL). One cycle consists of 28 days. Administration of belvarafenib should occur BID on every day of each 28-day cycle. |
実験的Cohort K: Rearranged During Transfection (RET) Fusion-positive Tumors (Excluding NSCLC) Participants with RET fusion-positive tumors will self-administer pralsetinib orally at home (except on clinic days) on a continuous daily dosing regimen at a dose of 400 mg/day (four 100-mg capsules per day) for adult and pediatric participants ≥ 12 and \< 18 years of age. A treatment cycle consists of 4 weeks (28 days). Note: Cohort K has been closed for enrollment. | Pralsetinib Pralsetinib will be self-administered by participants orally at home (except on clinic days) on a continuous daily dosing regimen at a dose of 400 mg/day (four 100-mg capsules per day) for adult and pediatric participants ≥ 12 and \< 18 years of age. A treatment cycle consists of 4 weeks (28 days). |
実験的Cohort L: KRAS G12C-positive Tumors (Excluding NSCLC and Colorectal Cancer [CRC]) Participants with kirsten rat sarcoma virus (KRAS) G12C-positive tumors will self-administer divarasib (GDC-6036) orally at home (except on clinic days). | Divarasib Divarasib will be self-administered by participants orally at home (except on clinic days) on a continuous daily dosing regimen for both adult and pediatric participants. A treatment cycle consists of 3 weeks (21 days). |
実験的Cohort M: Ataxia-telangiectasia Mutated (ATM) Loss of Function (LOF) Tumors Participants with ATM LOF tumors will self-administer camonsertib orally at home (except on clinic days). | Camonsertib Camonsertib will be self-administered by participants orally at home (except on clinic days). A treatment cycle consists of 3 weeks and will be given on days 1-3 and days 8-10 of every 21-day cycle. |
実験的Cohort N: SETD2 LOF Tumors Participants with methyltransferase SET (Su(var) 3-9) Enhancer of zest and Trithorax) domain-containing 2 (SETD2) LOF tumors will self-administer camonsertib orally at home (except on clinic days). | Camonsertib Camonsertib will be self-administered by participants orally at home (except on clinic days). A treatment cycle consists of 3 weeks and will be given on days 1-3 and days 8-10 of every 21-day cycle. |
主要評価項目
副次評価項目
| 評価指標 | 指標の説明 | 時間枠 |
|---|---|---|
All Cohorts: Independent Review Committee (IRC)-assessed Objective Response Rate (ORR) Based on Confirmed Objective Response (OR) per Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v1.1) | Confirmed objective response indicates ≥4 weeks after initial documentation of response. | Approximately up to 12 years |
| 評価指標 | 指標の説明 | 時間枠 |
|---|---|---|
All Cohorts: IRC-assessed Duration of Response (DOR) per RECIST v1.1 | Approximately up to 12 years | |
All Cohorts: IRC-assessed Clinical Benefit Rate (CBR) per RECIST v1.1 | Approximately up to 12 years | |
All Cohorts: IRC-assessed Progression-free Survival (PFS) per RECIST v1.1 | Approximately up to 12 years | |
All Cohorts: Investigator (INV)-assessed ORR per RECIST v1.1 | Approximately up to 12 years | |
All Cohorts: INV-assessed DOR per RECIST v1.1 | Approximately up to 12 years | |
All Cohorts: INV-assessed CBR per RECIST v1.1 | Approximately up to 12 years | |
All Cohorts: INV-assessed PFS per RECIST v1.1 | Approximately up to 12 years | |
All Cohorts: IRC- and INV-assessed Time to Central Nervous System (CNS) Progression per RECIST v1.1 | Approximately up to 12 years | |
All Cohorts: Overall Survival (OS) | Approximately up to 12 years | |
Cohorts A, B, C, D, I, J, K: IRC-assessed CNS-ORR per Response Assessment in Neuro-oncology (RANO) | Approximately up to 12 years | |
Cohorts A, B, C, D, I, J, K: IRC-assessed CNS-DOR per RANO | Approximately up to 12 years | |
Cohorts A, B, C, D, I, J, K: IRC-assessed CNS-CBR per RANO | Approximately up to 12 years | |
Cohorts A, B, C, D, I, J, K: IRC-assessed CNS-PFS per RANO | Approximately up to 12 years | |
Cohorts A, B, C, D, I, J, K: INV-assessed CNS-ORR per RANO | Approximately up to 12 years | |
Cohorts A, B, C, D, I, J, K: INV-assessed CNS-DOR per RANO | Approximately up to 12 years | |
Cohorts A, B, C, D, I, J, K: INV-assessed CNS-CBR per RANO | Approximately up to 12 years | |
Cohorts A, B, C, D, I, J, K: INV-assessed CNS-PFS per RANO | Approximately up to 12 years | |
Cohorts A, B, C, D, E, F, H, I, J, K, L, M, N: IRC-assessed ORR per International Neuroblastoma Response Criteria (INRC) | Approximately up to 12 years | |
Cohorts A, B, C, D, E, F, H, I, J, K, L, M, N: IRC-assessed DOR per INRC | Approximately up to 12 years | |
Cohorts A, B, C, D, E, F, H, I, J, K, L, M, N: IRC-assessed CBR per INRC | Approximately up to 12 years | |
Cohorts A, B, C, D, E, F, H, I, J, K, L, M, N: IRC-assessed PFS per INRC | Approximately up to 12 years | |
Cohorts A, B, C, D, E, F, H, I, J, K, L, M, N: INV-assessed ORR per INRC | Approximately up to 12 years | |
Cohorts A, B, C, D, E, F, H, I, J, K, L, M, N: INV-assessed DOR per INRC | Approximately up to 12 years | |
Cohorts A, B, C, D, E, F, H, I, J, K, L, M, N: INV-assessed CBR per INRC | Approximately up to 12 years | |
Cohorts A, B, C, D, E, F, H, I, J, K, L, M, N: INV-assessed PFS per INRC | Approximately up to 12 years | |
Cohorts A, B, C, D, I, J, K: IRC-assessed Intracranial (IC)-ORR per RECIST v1.1 | Approximately up to 12 years | |
Cohorts A, B, C, D, I, J, K: IRC-assessed IC-DOR per RECIST v1.1 | Approximately up to 12 years | |
Cohorts A, B, C, D, I, J, K: IRC-assessed IC-CBR per RECIST v1.1 | Approximately up to 12 years | |
Cohorts A, B, C, D, I, J, K: IRC-assessed IC-PFS Rate per RECIST v1.1 | Approximately up to 12 years | |
Cohorts A, B, C, D, I, J, K: INV-assessed IC-ORR per RECIST v1.1 | Approximately up to 12 years | |
Cohorts A, B, C, D, I, J, K: INV-assessed IC-DOR per RECIST v1.1 | Approximately up to 12 years | |
Cohorts A, B, C, D, I, J, K: INV-assessed IC-CBR per RECIST v1.1 | Approximately up to 12 years | |
Cohorts A, B, C, D, I, J, K: INV-assessed IC-PFS Rate per RECIST v1.1 | Approximately up to 12 years | |
Cohorts A and B: Percentage of Participants With Confirmed Deterioration as Assessed by the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) | The EORTC QLQ-C30 is a validated, reliable self-report measure. It consists of 30 questions that assess five aspects of participant functioning (physical, emotional, role, cognitive, and social), eight symptom scales (fatigue, nausea and vomiting, pain, dyspnea, insomnia, appetite loss, constipation, diarrhea) and global health/quality of life, with a recall period of the previous week. Scale scores can be obtained for the multi-item scales using rating scales of 4 or 7 points. | Approximately up to 12 years |
Cohorts A and B: Change From Baseline in the EORTC-QLQ-C30 Total Score | The EORTC QLQ-C30 is a validated, reliable self-report measure. It consists of 30 questions that assess five aspects of participant functioning (physical, emotional, role, cognitive, and social), eight symptom scales (fatigue, nausea and vomiting, pain, dyspnea, insomnia, appetite loss, constipation, diarrhea) and global health/quality of life, with a recall period of the previous week. Scale scores can be obtained for the multi-item scales using rating scales of 4 or 7 points. | Approximately up to 12 years |
Cohorts A and B: Percentage of Participants With a Clinical Meaningful Change on the Global Health Status, Physical Functioning, and Role Functioning Scores From the EORTC QLQ-C30 | The EORTC QLQ-C30 is a validated, reliable self-report measure. It consists of 30 questions that assess five aspects of participant functioning (physical, emotional, role, cognitive, and social), eight symptom scales (fatigue, nausea and vomiting, pain, dyspnea, insomnia, appetite loss, constipation, diarrhea) and global health/quality of life, with a recall period of the previous week. Scale scores can be obtained for the multi-item scales using rating scales of 4 or 7 points. | Approximately up to 12 years |
Cohorts A and B: Time to Confirmed Symptom Onset or Worsening From Tumor-related Symptom Scores From the EORTC QLQ-C30 and EORTC Item Library 71 (IL71) | The EORTC Item library includes stand-alone symptoms scales and an overall assessment of treatment bother to provide additional information not currently captured in the EORTC QLQ-C30. The scales use the same rating scale and recall period of previous week as the symptom scales in the EORTC QLQ-C30. | Approximately up to 12 years |
All Cohorts: Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) | AE severity will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 5 (NCI CTCAE v5.0.) | Approximately up to 12 years |
参加アシスタント
適格基準
対象年齢
小児, 成人, 高齢者
対象性別
全て
- Histologically or cytologically confirmed diagnosis of advanced and unresectable or metastatic solid malignancy
- Measurable disease as defined by RECIST v1.1, RANO, or INRC
- Performance status as follows: Participants aged ≥ 18 years: Eastern Cooperative Oncology Group (ECOG) Performance Status 0-2; Participants aged 16 to < 18 years: Karnofsky score ≥ 50%; Participants aged < 16 years: Lansky score ≥ 50%
- For participants aged ≥ 18 and < 18 years: adequate hematologic and end-organ function
- Disease progression on prior treatment, or previously untreated disease with no available acceptable treatment
- Adequate recovery from most recent systemic or local treatment for cancer
- Life expectancy ≥ 8 weeks
- Ability to comply with the study protocol, in the investigator's judgment
- For female participants of childbearing potential: Negative serum pregnancy test ≤ 14 days prior to initiating study treatment, agreement to remain abstinent or use single or combined contraception methods that result in a failure rate of < 1% per year for the period defined in the cohort-specific inclusion criteria; and agreement to refrain from donating eggs during the same period
- For male participants: Willingness to remain abstinent or use acceptable methods of contraception as defined in the cohort-specific inclusion criteria
- In addition to the general inclusion criteria above, participants must meet all of the cohort-specific inclusion criteria for the respective cohort
- Current participation or enrollment in another therapeutic clinical trial
- Any anticancer treatment within 2 weeks or 5 half-lives prior to start of study treatment
- Whole brain radiotherapy within 14 days prior to start of study treatment
- Stereotactic radiosurgery within 7 days prior to start of study treatment
- Pregnant or breastfeeding, or intending to become pregnant during the study
- History of or concurrent serious medical condition or abnormality in clinical laboratory tests that, in the investigator's judgment, precludes the participant's safe participation in and completion of the study or confounds the ability to interpret data from the study
- Incomplete recovery from any surgery prior to the start of study treatment that would interfere with the determination of safety or efficacy of study treatment
- Significant cardiovascular disease, such as New York Heart Association cardiac disease (Class II or higher), myocardial infarction, or cerebrovascular accident within 3 months prior to enrollment, unstable arrhythmias, or unstable angina
- History of another active cancer within 5 years prior to screening that may interfere with the determination of safety or efficacy of study treatment with respect to the qualifying solid tumor malignancy
- In addition to the general exclusion criteria above, in order to be enrolled in a treatment cohort of the study, participants must not meet any of the cohort-specific exclusion criteria
ロシュ試験中央連絡先
連絡先: Reference Study ID Number: BO41932 https://forpatients.roche.com/, 888-662-6728 (U.S. and Canada), [email protected]
163 24カ国の場所
National Cancer Center Hospital East, Chiba, 277-8577, Japan
撤回
Kindai University Hospital, Osaka, 589-8511, Japan
完了
National Cancer Center Hospital, Tokyo, 104-0045, Japan
完了
Alabama
Southern Cancer Center, Daphne, Alabama, 36526, United States
撤回
Arizona
Western Regional Medical Center at Cancer Treatment Centers of America, Goodyear, Arizona, 85338, United States
完了
California
City of Hope National Medical Center, Duarte, California, 91010, United States
撤回
Kaiser Permanente Los Angeles, Los Angeles, California, 90027, United States
実施中／登録終了
USC Norris Cancer Center, Los Angeles, California, 90033, United States
完了
Hoag Memorial Hospital, Newport Beach, California, 92658, United States
完了
UC Davis Comprehensive Cancer Center, Sacramento, California, 95817, United States
完了
University of California at San Francisco, San Francisco, California, 94158, United States
撤回
Sarcoma Oncology Center, Santa Monica, California, 90403, United States
撤回
Colorado
Children's Hospital Colorado, Aurora, Colorado, 80045, United States
撤回
Delaware
Christiana Care Health Srvcs, Newark, Delaware, 19713, United States
撤回
Florida
University of Florida, Gainesville, Florida, 32610, United States
撤回
Miami Cancer Institute of Baptist Health, Inc., Miami, Florida, 33176, United States
撤回
Ocala Oncology Center, Ocala, Florida, 34474, United States
撤回
Georgia
University Cancer & Blood Center, LLC, Athens, Georgia, 30607, United States
完了
Idaho
St. Alphonsus, Boise, Idaho, 83706, United States
完了
Illinois
Midwestern Regional Med Center, Zion, Illinois, 60099, United States
中止
Indiana
Horizon Oncology Research, Inc., Lafayette, Indiana, 47905, United States
完了
Maine
New England Cancer Specialists, Scarborough, Maine, 04074, United States
撤回
Maryland
Maryland Hematology & Oncology. P.A., Silver Spring, Maryland, 20904, United States
完了
Michigan
St. Joseph Mercy Hospital, Ann Arbor, Michigan, 48106, United States
撤回
Henry Ford Health System, Detroit, Michigan, 48202, United States
中止
Minnesota
University of Minnesota, Minneapolis, Minnesota, 55455, United States
撤回
Metro-Minnesota Community Oncology Research Consortium, Saint Louis Park, Minnesota, 55416, United States
募集中
Missouri
Washington University, St Louis, Missouri, 63110, United States
撤回
Montana
Intermountain Health St. Vincent Regional Hospital - Cancer Centers of Montana, Billings, Montana, 59102, United States
中止
Nebraska
Nebraska Methodist Hospital, Omaha, Nebraska, 68114, United States
撤回
Nevada
Comprehensive Cancer Centers of Nevada - Eastern Avenue, Las Vegas, Nevada, 89169, United States
撤回
New Hampshire
Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, 03756, United States
撤回
New Jersey
Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, 08901, United States
中止
New Mexico
University of New Mexico, Albuquerque, New Mexico, 87131, United States
中止
New York
National Translational Research Group, New York, New York, 10028, United States
撤回
Icahn School of Medicine at Mount Sinai, New York, New York, 10029, United States
完了
Memorial Sloan Kettering Cancer Center, New York, New York, 11101, United States
中止
New York Cancer and Blood Specialists - Setauket Medical Oncology, Port Jefferson Station, New York, 11776, United States
撤回
Montefiore Einstein Center for Cancer Care, The Bronx, New York, 10461, United States
完了
Eastchester Center for Cancer Care, The Bronx, New York, 10469, United States
撤回
Ohio
Barrett Cancer Center, Cincinnati, Ohio, 45219, United States
完了
Oncology Hematology Care Inc, Cincinnati, Ohio, 45242, United States
完了
Oregon
Providence Portland Medical Center, Portland, Oregon, 97213, United States
撤回
Pennsylvania
Consultants in Medical Oncology and Hematology, Broomall, Pennsylvania, 19008, United States
完了
Alliance Cancer Specialists, Horsham, Pennsylvania, 19044, United States
完了
Virginia Cancer Specialists - Leesburg, Leesburg, Pennsylvania, 20176, United States
完了
Cancer Treatment Centers of America, Philadelphia, Pennsylvania, 19124, United States
完了
The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, 19401, United States
撤回
South Carolina
PRISMA Health - Greenville, Greenville, South Carolina, 29605, United States
撤回
Tennessee
The West Clinic, Germantown, Tennessee, 38138, United States
完了
St. Jude Children'S Research Hospital, Memphis, Tennessee, 38105, United States
実施中／登録終了
Texas
Texas Oncology - Central South, Austin, Texas, 78731, United States
実施中／登録終了
Mary Crowley Medical Research Center, Dallas, Texas, 75230, United States
募集中
Texas Oncology - Baylor Charles A. Sammons Cancer Center, Dallas, Texas, 75246, United States
中止
Cook Childrens Medical Center, Fort Worth, Texas, 76104, United States
撤回
The University of Texas MD Anderson Cancer Center, Houston, Texas, 77030-4009, United States
完了
Texas Oncology- Northeast Texas, Tyler, Texas, 75702, United States
完了
Washington
Northwest Medical Specialties, PLLC, Tacoma, Washington, 98405, United States
完了
Wisconsin
Froedtert and The Medical College of Wisconsin, Milwaukee, Wisconsin, 53226, United States
募集中
New South Wales
Kinghorn Cancer Centre, Darlinghurst, New South Wales, 2010, Australia
完了
Sydney Children's Hospital, Randwick, New South Wales, 2031, Australia
撤回
Northern Territory
Royal Darwin Hospital, Tiwi, Northern Territory, 0810, Australia
撤回
Queensland
Princess Alexandra Hospital, Woolloongabba, Queensland, 4102, Australia
募集中
Victoria
Peter MacCallum Cancer Centre, Melbourne, Victoria, 3000, Australia
完了
Royal Children's Hospital, Parkville, Victoria, 3052, Australia
募集中
Cliniques Universitaires St-Luc, Brussels, 1200, Belgium
募集中
GHdC Site Les Viviers, Charleroi, 6060, Belgium
完了
UZ Antwerpen, Edegem, 2650, Belgium
撤回
UZ Gent, Ghent, 9000, Belgium
募集中
UZ Leuven Gasthuisberg, Leuven, 3000, Belgium
完了
Rio Grande do Sul
Hospital Moinhos de Vento, Porto Alegre, Rio Grande do Sul, 90035-001, Brazil
撤回
São Paulo
Hospital Sírio-Libanês, São Paulo, São Paulo, 01308-050, Brazil
撤回
Hospital Sírio-Libanês, São Paulo, São Paulo, 01308-050, Brazil
募集中
Hospital A. C. Camargo, São Paulo, São Paulo, 01509-010, Brazil
実施中／登録終了
Clínica Onco Star - Rede D'Or, São Paulo, São Paulo, 04543-000, Brazil
実施中／登録終了
British Columbia
BC Cancer ? Vancouver, Vancouver, British Columbia, V5Z 1J3, Canada
募集中
Ontario
London Health Sciences Centre · Victoria Hospital, London, Ontario, N6A 5W9, Canada
撤回
The Ottawa Hospital - General Campus, Ottawa, Ontario, K1H 8L6, Canada
募集中
The Hospital for Sick Children, Toronto, Ontario, M5G 1H3, Canada
募集中
Princess Margaret Cancer Center, Toronto, Ontario, M5G 2M9, Canada
撤回
Quebec
McGill University Health Center, Montreal, Quebec, H4A 3J1, Canada
撤回
Beijing Cancer Hospital, Beijing, 100142, China
募集中
Beijing Children's Hospital, Capital Medical University, Beijing, China
募集中
The First Hospital of Jilin University, Changchun, 130021, China
撤回
Jilin Cancer Hospital, Changchun, 132013, China
撤回
West China Hospital - Sichuan University, Chengdu, 610047, China
募集中
Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, 200092, China
募集中
Shanghai East Hospital, Shanghai, 200126, China
撤回
Zhongshan Hospital Fudan Unvierstiy, Shanghai, China
募集中
Tianjin Cancer Hospital, Tianjin, 300060, China
実施中／登録終了
First Affiliated Hospital of Medical College of Xi'an Jiaotong University, Xi'an, 710061, China
実施中／登録終了
Aarhus Universitetshospital, Aarhus N, 8200, Denmark
撤回
Rigshospitalet, København Ø, 2100, Denmark
実施中／登録終了
Institut Bergonie, Bordeaux, 33076, France
実施中／登録終了
Centre Oscar Lambret, Lille, 59020, France
完了
Centre Leon Berard, Lyon, 69373, France
実施中／登録終了
Hopital de la Timone, Marseille, 13005, France
実施中／登録終了
Institut Universitaire du Cancer de Toulouse-Oncopole, Toulouse, 31059, France
実施中／登録終了
Institut de Cancerologie Gustave-Roussy (IGR), Villejuif, 94805, France
実施中／登録終了
Uniklinik Essen, Essen, 45122, Germany
完了
Georg-August-Uniklinik, Göttingen, 37075, Germany
完了
Universitätsklinikum Hamburg-Eppendorf Onkologisches Zentrum Medizinische Klinik II, Hamburg, 20246, Germany
撤回
Medizinische Hochschule Zentrum Innere Medizin Abt.Gastroenterologie, Endokrinologie und Hepatologie, Hanover, 30625, Germany
撤回
SLK-Kliniken Heilbronn GmbH;Klinik für Innere Medizin III, Heilbronn, 74078, Germany
実施中／登録終了
Praxis für Hämatologie, Onkologie und Palliativmedizin, Mönchengladbach, 41066, Germany
完了
Klinikum der Universität München, Campus Großhadern, München, 81377, Germany
撤回
Universtitätsklinikum Ulm, Ulm, 89081, Germany
撤回
Uniklinikum, Comprehensive Cancer Center Mainfranken, Würzburg, 97078, Germany
撤回
Hong Kong Children's Hospital, Hong Kong, Hong Kong
募集中
Prince of Wales Hospital, Shatin, Hong Kong
募集中
Rambam Health Care Campus, Haifa, 3109601, Israel
募集中
Hadassah University Hospital - Ein Kerem, Jerusalem, 9112001, Israel
募集中
Rabin MC, Petah Tikva, 4941492, Israel
募集中
Sheba Medical Center, Ramat Gan, 5262100, Israel
募集中
Sourasky / Ichilov Hospital, Tel Aviv, 6423906, Israel
募集中
Campania
Istituto Nazionale Tumori Fondazione G. Pascale, Naples, Campania, 80131, Italy
撤回
Lazio
Ospedale Pediatrico Bambino Gesù - IRCCS, Rome, Lazio, 00165, Italy
募集中
Policlinico Universitario Agostino Gemelli IRCCS, Rome, Lazio, 00168, Italy
実施中／登録終了
Lombardy
Asst Degli Spedali Civili Di Brescia, Brescia, Lombardy, 25100, Italy
実施中／登録終了
Irccs Istituto Nazionale Dei Tumori (Int), Milan, Lombardy, 20133, Italy
募集中
Istituto Nazionale Tumori di Milano, Milan, Lombardy, 20133, Italy
募集中
Piedmont
Dipartimento di Scienze Pediatriche Adolescenza, Turin, Piedmont, 10126, Italy
募集中
Tuscany
Azienda Ospedaliera Meyer, Florence, Tuscany, 50139, Italy
撤回
Azienda Ospedaliera Universitaria Senese, U.O.C. Immunoterapia Oncologica, Siena, Tuscany, 53100, Italy
募集中
Auckland City Hospital, Cancer and Blood Research, Auckland, 1023, New Zealand
実施中／登録終了
Uniwersyteckie Centrum Kliniczne, Klinika Onkologii i Radioterapii, Gda?sk, 80-214, Poland
実施中／登録終了
Narod.Inst.Onkol. im. M.Sklodowskiej - Curie-Panst.Inst.Bad, Warsaw, 02-781, Poland
実施中／登録終了
IPO do Porto, Porto, 4200-072, Portugal
募集中
PanOncology Trials, San Juan, 00935, Puerto Rico
完了
National University Hospital, Singapore, 119228, Singapore
募集中
National Cancer Centre, Singapore, 168583, Singapore
実施中／登録終了
Medical Oncology Centre of Rosebank, Johannesburg, 2196, South Africa
撤回
Seoul National University Bundang Hospital, Gyeonggi-do, 13620, South Korea
実施中／登録終了
Seoul National University Hospital- Adult Site, Seoul, 03080, South Korea
実施中／登録終了
Seoul National University Hospital- Pediatric Site, Seoul, 03080, South Korea
完了
Severance Hospital, Yonsei University Health System, Seoul, 03722, South Korea
完了
Asan Medical Center, Seoul, 05505, South Korea
実施中／登録終了
Samsung Medical Center- Adult Site, Seoul, 06351, South Korea
実施中／登録終了
Samsung Medical Center- Pediatric Site, Seoul, 06351, South Korea
実施中／登録終了
Barcelona
Hospital Sant Joan De Deu, Esplugues de Llobregas, Barcelona, 08950, Spain
募集中
Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Barcelona, 08035, Spain
募集中
Vall d?Hebron Institute of Oncology (VHIO), Barcelona, Barcelona, 08035, Spain
募集中
Hospital Infantil Universitario Nino Jesus, Madrid, 28009, Spain
募集中
Clinica Universidad de Navarra Madrid, Madrid, 28027, Spain
完了
START Madrid-FJD, Hospital Fundacion Jimenez Diaz, Madrid, 28040, Spain
募集中
Hospital Universitario 12 de Octubre, Madrid, 28041, Spain
募集中
Hospital Universitario La Paz, Madrid, 28046, Spain
募集中
START Madrid. Centro Integral Oncologico Clara Campal, Madrid, 28050, Spain
募集中
Hospital Universitario la Fe, Valencia, 46026, Spain
募集中
Universitätsspital Basel (USB), Basel, 4031, Switzerland
撤回
Ospedale Regionale di Bellinzona Medizin Onkologie, Bellinzona, 6500, Switzerland
撤回
Inselspital, Klinik und Poliklinik für Medizinische Onkologie, Bern, 3010, Switzerland
実施中／登録終了
Unversitätsspital Zürich, Zurich, 8091, Switzerland
撤回
Taichung Veterans General Hospital, Taichung, 40705, Taiwan
撤回
National Cheng Kung University Hospital, Tainan, 00704, Taiwan
募集中
Taipei Veterans General Hospital, Taipei, 112201, Taiwan
募集中
Chang Gung Memorial Hospital-Linkou, Taoyuan, 333, Taiwan
完了
National Taiwan University Hospital, Zhongzheng Dist., 10048, Taiwan
実施中／登録終了
Beatson West of Scotland Cancer Centre, Glasgow, G12 0YN, United Kingdom
完了
University College London Hospital, London, NW1 - 2PG, United Kingdom
完了
Guys and St Thomas NHS Foundation Trust, Guys Hospital, London, SE1 9RT, United Kingdom
撤回
Royal Manchester Children?s Hospital, Manchester, M13 9WL, United Kingdom
撤回
The Christie NHS Foundation Trust, Manchester, M20 4BX, United Kingdom
完了